SEPN

Based on Septerna, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Septerna do?

Septerna is a clinical-stage biotechnology company that discovers and develops oral small molecule drugs targeting G protein-coupled receptors. Its pipeline addresses conditions including hypoparathyroidism, chronic spontaneous urticaria, Graves' disease, thyroid eye disease, obesity, and type 2 diabetes. The company has not yet commercialized any products.

Does SEPN pay dividends?

No, Septerna does not pay a dividend. As a pre-revenue clinical-stage company, capital is reinvested entirely into research and clinical development. Dividend income is not part of the current investment profile for SEPN.

When does SEPN report earnings?

Septerna reports on a quarterly cadence standard for US-listed companies. Because the company is pre-revenue, reports center on pipeline updates, operating expenses, and cash position rather than product sales. Check Septerna's investor relations page for the latest schedule.

Is SEPN a good stock to buy?

UQS Score rates SEPN as Good overall. The Growth pillar is Strong and Valuation is Attractive, but Quality and Moat are both Weak — reflecting the realities of a pre-revenue biotech. Whether SEPN fits a portfolio depends on an investor's risk tolerance and time horizon. View the full pillar breakdown on UQS Pro.

Is SEPN overvalued?

The UQS Valuation pillar for SEPN is rated Attractive, suggesting the current market price may offer a reasonable entry point relative to the company's pipeline potential. Valuation for clinical-stage biotechs is inherently speculative and tied to clinical outcomes rather than current earnings.

How does SEPN compare to its competitors?

Septerna's GPCR-focused oral small molecule platform distinguishes it from peers like Savara, Biohaven, and Precigen, which pursue different therapeutic areas and drug modalities. Each company carries its own clinical and financial risk profile. The UQS platform provides side-by-side scoring for a more structured comparison.

What is SEPN's market cap bracket?

Septerna is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large- or mega-cap peers.

Who founded Septerna?

Septerna was incorporated in 2019 under the name GPCR NewCo, Inc. and rebranded to Septerna Inc. in June 2021. Founding details and leadership history are publicly available through the company's SEC filings and investor relations materials.

Is SEPN a long-term quality investment?

As a long-term quality indicator, UQS rates SEPN as Good — driven by a Strong Growth profile and Attractive Valuation. However, Weak Quality and Moat scores reflect the absence of commercial revenue and established competitive advantages. Long-term quality will depend heavily on clinical success and eventual commercialization.

What is the main competitive advantage of Septerna?

Septerna's primary differentiator is its proprietary GPCR drug discovery platform, which is designed to generate oral small molecule candidates across multiple disease areas. Oral dosing is a potential advantage over injectable biologics in patient convenience and market adoption, though competitive advantages remain early-stage.

What sector does SEPN belong to?

Septerna operates in the Healthcare sector, specifically within clinical-stage biotechnology. The company's pipeline spans endocrinology, immunology, inflammation, and metabolic diseases — areas with significant unmet medical need and active competitive development.

Is SEPN a growth stock or value stock?

Based on UQS pillar labels, SEPN leans toward a growth profile — the Growth pillar is rated Strong and Valuation is Attractive. It is not a traditional value stock, as there are no current earnings or revenue. It is best characterized as a speculative growth opportunity tied to clinical pipeline outcomes.

Septerna, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Septerna, Inc. is growing rapidly with strong revenue and earnings expansion.

Septerna, Inc. maintains a reasonable risk profile with manageable debt levels.

Septerna, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.

Septerna, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SEPN.

The UQS (Unified Quality Score) for Septerna, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Septerna, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Septerna, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.